Biodexa Pharmaceuticals PLC Tech Stack

Biodexa Pharmaceuticals PLC uses 8 technology products and services including Microsoft Excel, Google Cloud, Backbone.js, and more. Explore Biodexa Pharmaceuticals PLC's tech stack below.

Microsoft Excel

Editors

Google Cloud

Infrastructure As A Service

Backbone.js

Javascript Frameworks

jQuery Mobile

Mobile Frameworks

Yoast SEO

Search Engines

Google Search Console

Web Analytics

Nginx

Web Servers

Apache

Web Servers

Biodexa Pharmaceuticals PLC's Email Address Formats

Biodexa Pharmaceuticals PLC uses at least 2 format(s):

Biodexa Pharmaceuticals PLC Email Formats	Example	Percentage
First.Last@midatechpharma.com	John.Doe@midatechpharma.com	90%
Last.First@midatechpharma.com	Doe.John@midatechpharma.com	5%
F.Last@midatechpharma.com	J.Doe@midatechpharma.com	3%
FirstLast@midatechpharma.com	JohnDoe@midatechpharma.com	2%
First.Last@biodexapharma.com	John.Doe@biodexapharma.com	100%

Biodexa Pharmaceuticals PLC Email Formats

Example

Percentage

First.Last@midatechpharma.com

John.Doe@midatechpharma.com

90%

Last.First@midatechpharma.com

Doe.John@midatechpharma.com

F.Last@midatechpharma.com

J.Doe@midatechpharma.com

FirstLast@midatechpharma.com

JohnDoe@midatechpharma.com

First.Last@biodexapharma.com

John.Doe@biodexapharma.com

100%

Frequently Asked Questions

Where is Biodexa Pharmaceuticals PLC's headquarters located?

Biodexa Pharmaceuticals PLC's main headquarters is located at 1 Caspian Point Caspian Way Caerdydd, Wales cf10 4dq United Kingdom. The company has employees across 2 continents, including EuropeNorth America.

What is Biodexa Pharmaceuticals PLC's stock symbol?

Biodexa Pharmaceuticals PLC is a publicly traded company; the company's stock symbol is BDRX.

What is Biodexa Pharmaceuticals PLC's official website and social media links?

Biodexa Pharmaceuticals PLC's official website is biodexapharma.com and has social profiles on LinkedIn.

What is Biodexa Pharmaceuticals PLC's SIC code NAICS code?

Biodexa Pharmaceuticals PLC's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Biodexa Pharmaceuticals PLC have currently?

As of June 2026, Biodexa Pharmaceuticals PLC has approximately 25 employees across 2 continents, including EuropeNorth America. Key team members include Chief Executive Officer: S. S.Chief Business Officer: S. E.Vice President Clinical Operations: J. K.. Explore Biodexa Pharmaceuticals PLC's employee directory with LeadIQ.

What industry does Biodexa Pharmaceuticals PLC belong to?

Biodexa Pharmaceuticals PLC operates in the Biotechnology Research industry.

What technology does Biodexa Pharmaceuticals PLC use?

Biodexa Pharmaceuticals PLC's tech stack includes Microsoft ExcelGoogle CloudBackbone.jsjQuery MobileYoast SEOGoogle Search ConsoleNginxApache.

What is Biodexa Pharmaceuticals PLC's email format?

Biodexa Pharmaceuticals PLC's email format typically follows the pattern of First.Last@midatechpharma.com. Find more Biodexa Pharmaceuticals PLC email formats with LeadIQ.

When was Biodexa Pharmaceuticals PLC founded?

Biodexa Pharmaceuticals PLC was founded in 2000.

Biodexa Pharmaceuticals PLC

Q: How many employees does Biodexa Pharmaceuticals PLC have currently?

Biodexa Pharmaceuticals PLC has approximately 25 employees.

Q: What technology does Biodexa Pharmaceuticals PLC use?

Biodexa Pharmaceuticals PLC's tech stack includes Ninja Forms, PWA, easy pie chart, Tippy.js, Backbone.js.

Q: What is Biodexa Pharmaceuticals PLC's NAICS code?

Biodexa Pharmaceuticals PLC's NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Biotechnology ResearchWales, United Kingdom11-50 Employees

Biodexa Pharmaceuticals PLC is a clinical-stage biotechnology company focused on developing therapies for diseases with high unmet medical need. Its lead program, eRapa, is advancing toward a phase 3 registration study in familial adenomatous polyposis, a rare condition where treatment options are limited and progression can lead to colorectal cancer. Beyond FAP, the company is pursuing research in type 1 diabetes and brain cancers.

Headquartered in Cardiff, Wales, Biodexa operates in the biotechnology research sector and maintains a relatively small team. It is publicly traded on Nasdaq under the ticker BDRX. In 2026, the company announced a manufacturing partnership with Syngene International to produce MTX240’s active ingredient and dosage form.

Insights

Similar companies to Biodexa Pharmaceuticals PLC

Glenmark Pharmaceuticals Ltd.

CALYX

LGM Pharma